- Home
- ECO vs BHVN Comparison
ECO vs BHVN Comparison
Compare ECO & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECO | BHVN |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | ECO | BHVN |
|---|---|---|
| Price | $40.33 | $11.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 15 |
| Target Price | ★ $37.00 | $30.36 |
| AVG Volume (30 Days) | 447.8K | ★ 2.9M |
| Earning Date | 02-18-2026 | 03-02-2026 |
| Dividend Yield | ★ 5.26% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $349,886,578.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.10 | N/A |
| P/E Ratio | $20.48 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.91 | $7.48 |
| 52 Week High | $41.31 | $44.28 |
Technical Indicators
Market Signals| Indicator | ECO | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 56.25 | 45.86 |
| Support Level | $38.38 | $10.61 |
| Resistance Level | $41.22 | $12.90 |
| Average True Range (ATR) | 1.02 | 0.80 |
| MACD | -0.13 | -0.23 |
| Stochastic Oscillator | 57.25 | 17.66 |
Price Performance
Historical ComparisonAbout ECO Okeanis Eco Tankers Corp.
Okeanis Eco Tankers Corp owns and operates tanker vessels in Greece. The business of the company is to own, charter out, and operate tanker vessels. The company owns, through its vessel-owning subsidiaries, a fleet of around seven tanker vessels and has around eight tanker vessels on order. The sailing fleet consists of around six modern Suezmax tankers and eight VLCC tankers.
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.